Viozan

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sibenadet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.
Libraries of dibasic compounds designed around the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™) have… (More)
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2011
2011
Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were… (More)
Is this relevant?
2007
2007
Long-term use ofViozanTM ( sibenadet HCI ) in patients with chronic obstructive pulmonary disease : results of a I-year study
Viozan TM (sibenadet HCI,AR-C68397AA) is a novel dual D 2 dopamine receptor, 132-adrenoceptor agonist that has been investigated… (More)
  • figure I
  • table 5
Is this relevant?
2003
2003
Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study.
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist that has been investigated… (More)
Is this relevant?
2003
2003
The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, developed specifically to… (More)
  • figure I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2003
2003
Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications.
The development of novel drugs for the treatment of chronic obstructive pulmonary disease (COPD) poses significant challenges… (More)
Is this relevant?
2003
2003
Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms.
Viozan, (Sibenadet HCl, AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator… (More)
Is this relevant?
2003
2003
Utilization of health care services by patients with chronic obstructive pulmonary disease.
In order to identify healthcare resource use patterns associated with chronic obstructive pulmonary disease (COPD), resource… (More)
Is this relevant?
2002
2002
Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD.
Sensory nerves regulate central and local reflexes such as airway plasma leakage, and cough and their function may be enhanced… (More)
Is this relevant?
2001
2001
Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by β2-adrenoceptors
The mechanism by which 2(3H)-benzothiazolone, 4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulphonyl]ethyl]amino]ethyl… (More)
Is this relevant?